Klin Onkol. 2021 Spring;34(Supplementum 1):54-64. doi: 10.48095/ccko2021S54.
Immunotherapy with check-point inhibitors has demonstrated remarkable therapeutic benefits in many oncological diagnoses, including non-small cell lung cancer (NSCLC). Based on the data from clinical trials, it has become an important part of the NSCLC treatment algorithm. Treatment with programmed cell death protein 1 / programmed death-ligand 1 inhibitors can be indicated in various ways: as monotherapy or combination of immunotherapy with cytotox--ic T-lymphocyte antigen 4 inhibitors or in combination with other treatment modalities - chemotherapy, antiangiogenic therapy and radiotherapy. Regarding new spectrum of immune-related side effects, which require quick diagnosis and treatment, there is great urge to identify immunotherapy predictive biomarkers.
免疫检查点抑制剂在许多肿瘤学诊断中显示出显著的治疗益处，包括非小细胞肺癌（NSCLC）。基于临床试验的数据，它已成为 NSCLC 治疗算法的重要组成部分。程序性细胞死亡蛋白 1/程序性死亡配体 1 抑制剂的治疗可以通过多种方式指示：作为单药治疗或与细胞毒性 T 淋巴细胞抗原 4 抑制剂的免疫疗法联合治疗，或与其他治疗方式联合治疗-化疗、抗血管生成治疗和放射治疗。鉴于需要快速诊断和治疗的新的免疫相关副作用谱，迫切需要确定免疫治疗预测生物标志物。
